UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

New Promise and Opportunities for Allosteric Kinase Inhibitors

Angewandte Chemie International Edition, 2020-08, Vol.59 (33), p.13764-13776

International ed. in English, 2020

Volltextzugriff (PDF)

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

Medicinal research reviews, 2018-09, Vol.38 (5), p.1550-1581

2018

Volltextzugriff (PDF)

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects

Journal of medicinal chemistry, 2019-03, Vol.62 (6), p.2905-2915

2019

Volltextzugriff (PDF)

The Documentary: Politics, Emotion, Culture

Smaill, B

1, 2009

Volltextzugriff (PDF)

TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure

ChemMedChem, 2019-02, Vol.14 (4), p.494-500

2019

Volltextzugriff (PDF)

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Clinical cancer research, 2021-03, Vol.27 (5), p.1463-1475

2021

Volltextzugriff (PDF)

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

Journal of structural biology, 2015-12, Vol.192 (3), p.539-544

2015

Volltextzugriff (PDF)

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

Cells (Basel, Switzerland), 2021-04, Vol.10 (5), p.1006

2021

Volltextzugriff (PDF)

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility

Biochemical journal, 2015-10, Vol.471 (2), p.131-153

2015

Volltextzugriff (PDF)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Clinical and translational radiation oncology, 2019-02, Vol.15, p.62-69

2019

Volltextzugriff (PDF)

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

Journal of medicinal chemistry, 2020-10, Vol.63 (19), p.10726-10741

2020

Volltextzugriff (PDF)

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623

International journal of molecular sciences, 2024-06, Vol.25 (12), p.6593

2024

Volltextzugriff (PDF)

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Journal of medicinal chemistry, 2020-12, Vol.63 (23), p.14404-14424

2020

Volltextzugriff (PDF)

Electrophysiology and 3D-imaging reveal properties of human intracardiac neurons and increased excitability with atrial fibrillation

The Journal of physiology, 2024-04

2024

Volltextzugriff (PDF)

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Journal of medicinal chemistry, 2022-01, Vol.65 (1), p.58-83

2022

Volltextzugriff (PDF)

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents

Molecules (Basel, Switzerland), 2021-06, Vol.26 (11), p.3327

2021

Volltextzugriff (PDF)

Allosterische Kinaseinhibitoren – Erwartungen und Chancen

Angewandte Chemie, 2020-08, Vol.132 (33), p.13868-13881

2020

Volltextzugriff (PDF)

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling

Frontiers in pharmacology, 2022-02, Vol.13, p.803602-803602

2022

Volltextzugriff (PDF)

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

Molecules (Basel, Switzerland), 2020-10, Vol.25 (21), p.4888

2020

Volltextzugriff (PDF)

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia

Blood cancer journal (New York), 2024-11, Vol.14 (1), p.192-13, Article 192

2024

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Journal of medicinal chemistry, 2000-04, Vol.43 (7), p.1380-1397

2000

Volltextzugriff (PDF)

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954

Biochemical pharmacology, 2010-03, Vol.79 (5), p.678-687

2010

Volltextzugriff (PDF)

TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery

Drug discovery today, 2021-10, Vol.26 (10), p.2445-2455

2021

Volltextzugriff (PDF)

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations

Journal of medicinal chemistry, 2023-09, Vol.66 (17), p.11656-11671

2023

Volltextzugriff (PDF)

Application of Micro-Computed Tomography With Iodine Staining to Cardiac Imaging, Segmentation, and Computational Model Development

IEEE transactions on medical imaging, 2013-01, Vol.32 (1), p.8-17

2013

Volltextzugriff (PDF)

1 – 25 von 306

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(250)
Mit Volltextzugriff
(278)

Publikationsform

Sprache

Englisch
(306)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(212)
Life Sciences & Biomedicine
(179)
Humans
(103)
Animals
(76)
Biological And Medical Sciences
(60)
Pharmacology & Pharmacy
(51)
Female
(41)
Medical Sciences
(41)
Technology
(38)
Chemistry, Medicinal
(37)
Cardiovascular System & Cardiology
(33)
Adult
(32)
Male
(32)
Cardiac & Cardiovascular Systems
(31)
Heart
(31)
Infectious Diseases
(28)
Engineering
(27)
Engineering, Biomedical
(26)
Fundamental And Applied Biological Sciences. Psychology
(24)
Physiology
(24)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

New Promise and Opportunities for Allosteric Kinase Inhibitors

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry

Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects

The Documentary: Politics, Emotion, Culture

TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed

Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy

Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials

Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623

Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics

Electrophysiology and 3D-imaging reveal properties of human intracardiac neurons and increased excitability with atrial fibrillation

Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors

Design, Synthesis and In-Vitro Biological Evaluation of Antofine and Tylophorine Prodrugs as Hypoxia-Targeted Anticancer Agents

Allosterische Kinaseinhibitoren – Erwartungen und Chancen

Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954

TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations

Application of Micro-Computed Tomography With Iodine Staining to Cardiac Imaging, Segmentation, and Computational Model Development

Suchergebnisse filtern